Cell-Targeted Medicines

Gene silencing. Precisely delivered.

Expanding what siRNA medicines can treat, and where they can act.

Scroll
Inflammaging

The burden of aging from chronic inflammatory disease.

What drives it
Senescent cells
Mitochondrial dysfunction
Oxidative stress
Visceral adiposity
Immune dysregulation
Gut dysbiosis

Chronic, low-grade inflammation

Halftoned fluorescence micrograph: a vessel lumen opening into a dense field of cell nuclei in grey, with scattered cells carrying Cy5-labelled siRNA shown in teal

Dysfunctional macrophages are key drivers — both causal and therapeutically actionable.

In vivo · Cy5-siRNA uptakeLoaded cells in teal; unlabelled nuclei in grey.
01

Inflammation

Inflammation that never resolves

02

Fibrosis

Repair that never switches off

03

Neurodegeneration

Maintenance turned to harm

04

Cardiorenal and vascular

Damage that accumulates

Problem · Target space

Most disease-driving biology remains inaccessible with conventional modalities.

Small molecules and antibodies need a binding pocket. Most disease-driving proteins don't have one.

siRNA doesn't need a pocket — it acts on the transcript, before the protein exists.

Human proteome · one square = 1%

~15%

“Druggable”

~85%

Beyond small molecules and antibodies

Targeting ligands

Each ligand opens a set of therapeutic programs.

01 · SC-1Program enabling

Immune targeted

Systemic and inhaled delivery to the tissue macrophage compartment. In vivo biodistribution and silencing.

Liver · Kidney · Spleen · PancreasSubqLung · Inhaled
02Discovery

Kidney

Two paths: one ligand targeting the proximal tubule, a second reaching deeper regions of the kidney. In vivo data.

Proximal tubuleDeeper nephron
03Discovery

CNS

Developing small targeting ligands for TfR and other receptor-mediated pathways to enable delivery across the BBB.

BBB deliveryIV / Subq
04Discovery

Lung · non-immune

Developing small targeting ligands for selective inhaled delivery to lung epithelial cells and fibroblasts.

EpithelialFibroblasts
05Discovery

Other

Further tissues in discovery.

0+Virtual glycan-protein interactions
0Tissue targets
0+Novel binders discovered
<0Week AI-to-validated-candidate cycle times

The future of drug delivery is written in sugar

CellCo is building the computational platform to decode, design, and deploy glycan-targeted therapeutics at scale.